15157 - ISTH "Controversies in Anticoagulation"

Through its educational arm, the ISTH Academy, the International Society on Thrombosis and Haemostasis (ISTH) has begun hosting a series of webinars on practical thrombosis and haemostasis issues that scientists and physicians frequently confront. These webinars will allot time for participants to ask questions and will cover the latest information on relevant topics.

How and when to monitor novel anticoagulants – Mark Crowther (Canada)
Dr. Crowther will discuss when (nearly never) and how (it is complicated) novel anticoagulants.

Heritable thrombophilias – diagnosis and management – Peter K. MacCallum (UK)
This presentation will focus on the pathophysiology, epidemiology and laboratory diagnosis of the heritable thrombophilias as well as the management of these abnormalities in clinical practice.

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of The Medical College of Wisconsin and International Society on Thrombosis and Haemostasis. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
 
Designation of Credit Statement:
The Medical College of Wisconsin designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
Please note: The course fee is $25.00 in addition to a $2.50 processing fee which is assessed for all electronic registrations.
 
More information and online registration:  http://www.prolibraries.com/isth/
 
 
Sponsored by an unrestricted educational grant from Instrumentation Laboratory 
 

Target Audience

  • Clinicians practicing in the field of venous thromboembolism
  • Researchers
  • Nurses
  • Allied Health Professionals
    • Providing a laboratory service
    • Those who manage anticoagulant therapy

Learning Objectives

At the conclusion of this activity, I will be able to:

  • Understand evidence for test that can determine if anticoagulants are present
  • Discuss where testing should, and should not, be used
  • Explore bleeding and other toxicity risks and their relationship to levels
  • Understanding of mechanisms whereby heritable thrombophilias predispose to venous thromboembolism
  • Epidemiology of the heritable thrombophilias including influence of family history
  • Basic laboratory diagnosis of the heritable thrombophilias and common influences on measurement of variables
  • Testing for and management of heritable thrombophilias in patients with venous thromboembolism
  • Testing for and management of heritable thrombophilias in asymptomatic individuals
Additional information

CME Coordinator Contact Information

Name: 
Cary Clark
Phone Number: 
+1 (919) 929-3807
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.
Course opens: 
02/25/2015
Course expires: 
02/25/2016
Cost:
$2.50
Planning Committee:
Yukio Ozaki
Geoff Barnes
Chris Ward
Cary Clark
Stephen Watson
 
 
Presenter:
Mark Crowther
Title of presentation: How and when to monitor novel anticoagulants
Description of presentation: Dr. Crowther will discuss when (nearly never) and how (it is complicated) novel anticoagulants.
Peter MacCallum
Title of presentation: Heritable thrombophilias – diagnosis and management
Description of presentation: This presentation will focus on the pathophysiology, epidemiology and laboratory diagnosis of the heritable thrombophilias as well as the management of these abnormalities in clinical practice.
 
Moderator:
Geoff Barnes
 
All persons in control of content have NO relevant financial relationships to disclose with the exception of the following persons:  
 
In accordance with the ACCME®  Standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved
NameCompanyRole
Mark CrowtherOctapharma, Bayer, Boehringer-Ingelheim, Janssen, Pfizer, Leo Pharma and Portola;Advisory Board
 

AKP America, Daichii, Bayer, Leo Pharma and Bayer;

Study Steering committees, or other research related activities for projects
 BMS-Pfizer alliance, Leo Pharma, Abbvie, Bayer, Celgene, Shire and CSL Behringpreparation of educational materials and/or presentations
Peter MacCallumLeo Pharmaceuticals, Bayer, Daiichi SankyoSpeaker, Consulting
Geoff BarnesBristol-Myers Squibb, Pfizer, Blue Cross-Blue Shield of MichiganPrimary Investigator & Co-Investigator

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.

Accreditation Period

Course opens: 
02/25/2015
Course expires: 
02/25/2016

Price

Cost:
$2.50
Please login or register to take this course.

Required Hardware/software

To view the webcast on your computer go to https://www.isth.org/  click the Events/Webinars tab and view the ISTH 2015 Archived Webinars

Participant Privacy